The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508delCFTRvariant
| Autor: | Pierre-Régis Burgel, Isabelle Sermet-Gaudelus, Isabelle Durieu, Reem Kanaan, Julie Macey, Dominique Grenet, Michele Porzio, Nathalie Coolen-Allou, Raphael Chiron, Christophe Marguet, Benoit Douvry, Nadine Dufeu, Isabelle Danner-Boucher, Pierre Foucaud, Lydie Lemonnier, Emmanuelle Girodon, Jennifer Da Silva, Clémence Martin |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | European Respiratory Journal. :2202437 |
| ISSN: | 1399-3003 0903-1936 |
| Popis: | BackgroundThe European Medicines Agency has approved the cystic fibrosis transmembrane conductance regulator (CFTR) modulator combination elexacaftor-tezacaftor-ivacaftor (ETI) for people with cystic fibrosis (pwCF) carrying at least one F508del variant. The United States Food and Drug Administration (FDA) also approved ETI for pwCF carrying one of 177 rare variants.MethodsAn observational study was conducted to evaluate the effectiveness of ETI in pwCF with advanced lung disease that were not eligible to ETI in Europe. All patients with no F508del variant and advanced lung disease (defined as having a percent predicted forced expiratory volume (ppFEV1)1.ResultsAmong the first 84 pwCF included in the program, ETI was effective in 45 (54%) and 39 (46%) were considered to be non-responders. Among the responders 22/45 (49%) carried aCFTRvariant that is not currently approved by FDA for ETI eligibility. Important clinical benefits, including suspending the indication for lung transplantation, a significant decrease in sweat chloride concentration by a median [IQR] −30 [-14;-43]mmol·l−1(n=42;p1by+10.0 [6.0; 20.5] (n=44,pConclusionClinical benefits were observed in a large subset of pwCF with advanced lung disease andCFTRvariants not currently approved for ETI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|